Clinical Trial Update: Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of the Cand5 RNA molecule for wet age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Cand5 (Cand5 siRNA)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED